• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bio-Techne Releases Second Quarter Fiscal 2025 Results

    2/5/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email

    MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2024.

    Second Quarter FY2025 Highlights

    • Second quarter organic revenue increased by 9% (9% reported) to $297.0 million.
    • GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago.
    • Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy workflow solutions, led to 8% organic growth in our Protein Sciences Segment (7% reported).
    • Strong commercial execution in Diagnostics & Spatial Biology led to 12% organic growth (12% reported) in the segment.

    The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted diluted EPS, adjusted net earnings, adjusted gross margin, adjusted operating income, adjusted tax rate, organic revenue, adjusted operating margin, earnings before interest, taxes, depreciation, and amortization (EBITDA), and adjusted EBITDA are non-GAAP measures that exclude certain items detailed later in this press release under the heading "Use of non-GAAP Adjusted Financial Measures." A reconciliation of GAAP to non-GAAP financial measures is included in this press release.

    "The Bio-Techne team once again executed at a high level and delivered strong second quarter results," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "It is encouraging to see early signs of improvement in the biopharma end-market, which was evident in our cell and gene therapy and protein analysis instrumentation businesses. We delivered this top-line result with a continued focus on profitability, which resulted in a 30.1% adjusted operating margin, an increase of 110 basis points sequentially."

    Kelderman added, "The Bio-Techne growth vectors empower the discovery of novel biological insights, the development and manufacturing of advanced therapeutics and, enable precision diagnostics. Our portfolio plays a key role in the healthy aging of global populations. The combination of this unique portfolio with the talented Bio-Techne team positions the Company for continued differentiated financial performance."

    Bio-Techne will host an earnings conference call today, February 5, 2025, at 8:00 a.m. CST. To listen, please dial 1-877-407-9208 or 1-201-493-6784 (for international callers), and reference conference ID 13751305. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.

    A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13751305. The replay will be available from 11:00 a.m. CST on Wednesday, February 5, 2025, until 11:00 p.m. CST on Wednesday, March 5, 2025.

    Second Quarter Fiscal 2025

    Revenue

    Net sales for the second quarter increased 9% to $297.0 million. Organic revenue increased 9% compared to the prior year. Foreign currency exchange and a business held-for-sale did not have a material impact.

    GAAP Earnings Results

    GAAP EPS was $0.22 per diluted share, versus $0.17 in the same quarter last year. GAAP operating income for the second quarter of fiscal 2025 increased 25% to $47.4 million, compared to $38.0 million in the second quarter of fiscal 2024. GAAP operating margin was 16.0%, compared to 13.9% in the second quarter of fiscal 2024. Current year GAAP operating margin was favorably impacted by volume leverage and a non-recurring prior year impairment of a business held-for-sale.

    Non-GAAP Earnings Results

    Adjusted EPS increased to $0.42 per diluted share compared to $0.40 in the same quarter last year. Adjusted operating income for the second quarter of fiscal 2025 increased 8% to $88.7 million, compared to $81.9 million in the second quarter of fiscal 2024. Adjusted operating margin remained flat at 30.1% for the second quarter of fiscal 2025 compared to the second quarter of fiscal 2024. Adjusted operating margin was impacted by favorable volume leverage offset by re-instatement of incentive compensation accruals.

    Segment Results

    Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.

    Protein Sciences Segment

    The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment's second quarter fiscal 2025 net sales were $211.6 million, an increase of 7% from $197.7 million for the second quarter of fiscal 2024. As of December 31, 2023, a business within the Protein Sciences Segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's second quarter fiscal 2025 operating results. The exclusion of fiscal 2025 sales related to this held-for-sale business reduced sales by 1%. Organic revenue growth was 8% for the second quarter of fiscal 2025, with foreign currency exchange not having a material impact. The Protein Sciences segment's operating margin increased to 41.2% in the second quarter of fiscal 2025 compared to 40.3% in the second quarter of fiscal 2024. The segment's operating margin increased primarily due to volume leverage offset by re-instatement of incentive compensation accruals.

    Diagnostics and Spatial Biology Segment

    The Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits, as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's second quarter fiscal 2025 net sales were $84.1 million, an increase of 12% from $75.4 million for the second quarter of fiscal 2024. Organic revenue growth was 12% for the second quarter of fiscal 2025, with foreign exchange not having a material impact. The Diagnostics and Spatial Biology segment's operating margin was 3.9% in the second quarter of fiscal 2025 compared to 6.0% in the second quarter of fiscal 2024. The segment's operating margin decreased primarily due to re-instatement of incentive compensation accruals, partially offset by favorable volume leverage.

    Use of non-GAAP Adjusted Financial Measures:

    This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. These non-GAAP measures include:

    • Organic revenue
    • Adjusted diluted earnings per share
    • Adjusted net earnings
    • Adjusted tax rate
    • Adjusted gross margin
    • Adjusted operating income
    • Adjusted operating margin
    • Earnings before interest, taxes, depreciation, and amortization (EBITDA)
    • Adjusted EBITDA

    We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

    Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in the fiscal years 2025 and 2024.

    Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs.  Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.

    The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.

    The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

    Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.

    Forward Looking Statements:

    Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

    For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

    Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­techne.com.

    Contact:       

    David Clair, Vice President, Investor Relations & Corporate Development



    [email protected]



    612-656-4416

     

    BIO-TECHNE CORPORATION

    CONSOLIDATED STATEMENTS OF EARNINGS

    (In thousands, except per share data)

    (Unaudited)

     





    QUARTER



    SIX MONTHS





    ENDED



    ENDED





    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023

    Net Sales



    $

    297,031



    $

    272,598



    $

    586,489



    $

    549,533

    Cost of sales





    103,145





    96,011





    209,586





    187,755

    Gross margin





    193,886





    176,587





    376,903





    361,778

    Operating Expenses:

























    Selling, general and administrative





    121,451





    115,667





    240,612





    220,998

    Research and development





    25,016





    22,916





    48,885





    46,914

    Total Operating Expenses





    146,467





    138,583





    289,497





    267,912

    Operating income





    47,419





    38,004





    87,406





    93,866

    Other income (expense)





    (4,543)





    (4,617)





    (4,359)





    (10,921)

    Earnings before income taxes





    42,876





    33,387





    83,047





    82,945

    Income taxes





    7,986





    5,922





    14,557





    4,486

    Net earnings



    $

    34,890



    $

    27,465



    $

    68,490



    $

    78,459

    Earnings per share:

























    Basic



    $

    0.22



    $

    0.17



    $

    0.43



    $

    0.50

    Diluted



    $

    0.22



    $

    0.17



    $

    0.42



    $

    0.49

    Weighted average common shares outstanding

























    Basic





    158,431





    157,533





    158,481





    157,826

    Diluted





    160,626





    160,060





    161,353





    161,001

     

    BIO-TECHNE CORPORATION

    CONSOLIDATED CONDENSED BALANCE SHEETS

    (In thousands)

    (Unaudited)



















    12/31/2024



    6/30/2024

    ASSETS













    Cash and equivalents



    $

    177,549



    $

    151,791

    Short-term available-for-sale investments





    —





    1,072

    Accounts receivable, net





    217,940





    241,394

    Inventories





    188,373





    179,731

    Current assets held-for-sale





    1,047





    9,773

    Other current assets





    49,731





    33,658

    Total current assets





    634,640





    617,419















    Property and equipment, net





    249,753





    251,154

    Right of use assets





    85,383





    91,285

    Goodwill and intangible assets, net





    1,425,658





    1,479,744

    Other assets





    274,990





    264,265

    Total assets



    $

    2,670,424



    $

    2,703,867















    LIABILITIES AND STOCKHOLDERS' EQUITY













    Accounts payable and accrued expenses



    $

    114,257



    $

    112,672

    Contract liabilities





    27,715





    27,930

    Income taxes payable





    3,141





    3,706

    Operating lease liabilities - current





    13,511





    12,920

    Other current liabilities





    2,632





    2,151

    Total current liabilities





    161,256





    159,379















    Deferred income taxes





    37,723





    55,863

    Long-term debt obligations





    300,000





    319,000

    Operating lease liabilities





    81,616





    87,618

    Other long-term liabilities





    11,337





    13,157

    Stockholders' equity





    2,078,492





    2,068,850

    Total liabilities and stockholders' equity



    $

    2,670,424



    $

    2,703,867

     

    BIO-TECHNE CORPORATION

    RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE

    (In thousands)

    (Unaudited)

































    QUARTER



    SIX MONTHS







    ENDED



    ENDED







    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023



    Total consolidated net sales



    $

    297,031



    $

    272,598



    $

    586,489



    $

    549,533



    Business held-for-sale1)





    1,849





    —





    4,152





    —



    Revenue from recurring operations



    $

    295,182



    $

    272,598



    $

    582,337



    $

    549,533































    Gross margin - GAAP



    $

    193,886



    $

    176,587



    $

    376,903



    $

    361,778



    Gross margin percentage - GAAP





    65.3

    %



    64.8

    %



    64.3

    %



    65.8

    %





























    Identified adjustments:



























    Costs recognized upon sale of acquired inventory



    $

    185



    $

    183



    $

    373



    $

    364



    Amortization of intangibles





    10,630





    11,790





    22,410





    23,656



    Stock-based compensation, inclusive of employer taxes





    395





    256





    667





    470



    Restructuring and restructuring-related costs





    2,691





    1,174





    7,589





    1,174



    Impact of business held-for-sale1)





    376





    —





    (182)





    —



    Adjusted gross margin



    $

    208,163



    $

    189,990



    $

    407,760



    $

    387,442



    Adjusted gross margin percentage2)





    70.5

    %



    69.7

    %



    70.0

    %



    70.5

    %





























    1)

    Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

    2)

    Adjusted gross margin percentage excludes both $1,849 and $4,152 of revenue and $(376) and $182 of gross margin for the three and six months ended for a business that has met the held-for-sale criteria.

     

    BIO-TECHNE CORPORATION

    RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE

    (In thousands)

    (Unaudited)

































    QUARTER



    SIX MONTHS







    ENDED



    ENDED







    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023



    Total consolidated net sales



    $

    297,031



    $

    272,598



    $

    586,489



    $

    549,533



    Business held-for-sale1)





    1,849





    —





    4,152





    —



    Revenue from recurring operations



    $

    295,182



    $

    272,598



    $

    582,337



    $

    549,533































    Operating income - GAAP



    $

    47,419



    $

    38,004



    $

    87,406



    $

    93,866



    Operating income percentage - GAAP





    16.0

    %



    13.9

    %



    14.9

    %



    17.1

    %





























    Identified adjustments:



























    Costs recognized upon sale of acquired inventory



    $

    185



    $

    183



    $

    373



    $

    364



    Amortization of intangibles





    18,559





    19,769





    38,300





    39,620



    Acquisition related expenses and other





    2,010





    (525)





    3,523





    (1,114)



    Certain litigation charges





    1,386





    —





    1,678





    —



    Stock-based compensation, inclusive of employer taxes





    15,238





    12,958





    25,875





    24,453



    Restructuring and restructuring-related costs





    3,287





    5,518





    14,309





    5,607



    Impairment of assets held-for-sale





    —





    6,038





    —





    6,038



    Impact of business held-for-sale1)





    627





    —





    479





    —



    Adjusted operating income



    $

    88,711



    $

    81,945



    $

    171,943



    $

    168,834



    Adjusted operating margin percentage2)





    30.1

    %



    30.1

    %



    29.5

    %



    30.7

    %





    1)

    Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

    2)

    Adjusted operating margin percentage excludes both $1,849 and $4,152 of revenue and $(627) and $(479) of operating income for the three and six months ended for a business that has met the held-for-sale criteria.

     

    BIO-TECHNE CORPORATION

    NON-GAAP ADJUSTED CONSOLIDATED NET EARNINGS and EARNINGS per SHARE

    (In thousands, except per share data)

    (Unaudited)



































    QUARTER



    SIX MONTHS







    ENDED



    ENDED







    12/31/2024



    12/31/2023





    12/31/2024



    12/31/2023



    Net earnings before taxes - GAAP



    $

    42,876



    $

    33,387





    $

    83,047



    $

    82,945



    Identified adjustments:





























    Costs recognized upon sale of acquired inventory





    185





    183







    373





    364



    Amortization of intangibles





    18,559





    19,769







    38,300





    39,620



    Amortization of Wilson Wolf intangible assets and acquired inventory





    2,489





    4,208







    4,979





    8,416



    Acquisition related expenses and other





    2,139





    (381)







    3,813





    (822)



    Certain litigation charges





    1,386





    —







    1,678





    —



    Stock-based compensation, inclusive of employer taxes





    15,238





    12,958







    25,875





    24,453



    Restructuring and restructuring-related costs





    3,287





    5,518







    14,309





    5,607



    Investment (gain) loss and other non-operating





    —





    —







    —





    (283)



    Impairment of assets held-for-sale





    —





    6,038







    —





    6,038



    Impact of business held-for-sale1)





    627





    —







    479





    —



    Net earnings before taxes - Adjusted



    $

    86,786



    $

    81,680





    $

    172,853



    $

    166,338



    Non-GAAP tax rate





    21.5

    %



    22.0

    %





    21.5

    %



    22.0

    %

    Non-GAAP tax expense



    $

    18,659



    $

    17,964





    $

    37,195



    $

    36,579



    Non-GAAP adjusted net earnings



    $

    68,127



    $

    63,716





    $

    135,658



    $

    129,759



    Earnings per share - diluted - Adjusted



    $

    0.42



    $

    0.40





    $

    0.84



    $

    0.81





    1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

     

    BIO-TECHNE CORPORATION

    NON-GAAP ADJUSTED TAX RATE

    (In percentages)

    (Unaudited)































    QUARTER



    SIX MONTHS





    ENDED



    ENDED





    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023

    GAAP effective tax rate



    18.6

    %



    17.7

    %



    17.5

    %



    5.4

    %

    Discrete items



    5.1





    8.3





    6.1





    18.0



    Annual forecast update



    (0.1)





    (2.6)





    —





    —



    Long-term GAAP tax rate



    23.6

    %



    23.4

    %



    23.6

    %



    23.4

    %

    Rate impact items

























    Stock based compensation



    (2.8)

    %



    (2.1)

    %



    (2.9)

    %



    (2.4)

    %

    Other



    0.7





    0.7





    0.8





    1.0



    Total rate impact items



    (2.1)

    %



    (1.4)

    %



    (2.1)

    %



    (1.4)

    %

    Non-GAAP adjusted tax rate



    21.5

    %



    22.0

    %



    21.5

    %



    22.0

    %

     

    BIO-TECHNE CORPORATION

    SEGMENT REVENUE

    (In thousands)

    (Unaudited)































    QUARTER



    SIX MONTHS





    ENDED



    ENDED





    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023

    Protein Sciences segment revenue



    $

    211,551



    $

    197,670



    $

    416,086



    $

    402,325

    Diagnostics and Spatial Biology segment revenue





    84,135





    75,408





    167,327





    148,204

    Other revenue1)





    1,849





    —





    4,152





    —

    lntersegment revenue





    (504)





    (480)





    (1,076)





    (996)

    Consolidated revenue



    $

    297,031



    $

    272,598



    $

    586,489



    $

    549,533



    1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

     

    BIO-TECHNE CORPORATION

    SEGMENT OPERATING INCOME

    (In thousands)

    (Unaudited)































    QUARTER



    SIX MONTHS





    ENDED



    ENDED





    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023

    Protein Sciences segment operating income



    $

    87,112



    $

    79,586



    $

    167,653



    $

    167,947

    Diagnostics and Spatial Biology segment operating income





    3,240





    4,556





    7,517





    5,082

    Segment operating income





    90,352





    84,142





    175,170





    173,029

    Corporate general, selling, and administrative





    (1,641)





    (2,197)





    (3,227)





    (4,195)

    Adjusted operating income





    88,711





    81,945





    171,943





    168,834

    Cost recognized upon sale of acquired inventory





    (185)





    (183)





    (373)





    (364)

    Amortization of intangibles





    (18,559)





    (19,769)





    (38,300)





    (39,620)

    Acquisition related expenses and other





    (2,010)





    525





    (3,523)





    1,114

    Certain litigation charges





    (1,386)





    —





    (1,678)





    —

    Stock-based compensation, inclusive of employer taxes





    (15,238)





    (12,958)





    (25,875)





    (24,453)

    Restructuring and restructuring-related costs





    (3,287)





    (5,518)





    (14,309)





    (5,607)

    Impairment of assets held-for-sale





    —





    (6,038)





    —





    (6,038)

    Impact of business held-for-sale1)





    (627)





    —





    (479)





    —

    Operating income



    $

    47,419



    $

    38,004



    $

    87,406



    $

    93,866





    1)

    Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

     

    BIO-TECHNE CORPORATION

    RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA

    (In thousands)

    (Unaudited)



























    QUARTER



    SIX MONTHS



    ENDED



    ENDED



    12/31/2024



    12/31/2023



    12/31/2024



    12/31/2023

    Net earnings

    $

    34,890



    $

    27,465



    $

    68,490



    $

    78,459

    Net interest expense (income)



    800





    3,513





    2,050





    7,516

    Depreciation and amortization



    27,084





    27,804





    55,221





    56,343

    Income taxes



    7,986





    5,922





    14,557





    4,486

    EBITDA



    70,760





    64,704





    140,318





    146,804

    Costs recognized upon sale of acquired inventory



    185





    183





    373





    364

    Amortization of Wilson Wolf intangible assets and acquired inventory



    2,489





    4,208





    4,979





    8,416

    Acquisition related expenses and other



    2,139





    (381)





    3,813





    (822)

    Certain litigation charges



    1,386





    —





    1,678





    —

    Stock-based compensation, inclusive of employer taxes



    15,238





    12,958





    25,875





    24,453

    Restructuring and restructuring-related costs



    3,287





    5,518





    14,309





    5,607

    Investment (gain) loss and other non-operating



    —





    —





    —





    (283)

    Impairment of assets held-for-sale



    —





    6,038





    —





    6,038

    Impact of business held-for-sale1)



    627





    —





    479





    —

    Adjusted EBITDA

    $

    96,111



    $

    93,228



    $

    191,824



    $

    190,577



    1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria.

     

    BIO-TECHNE CORPORATION

    CONDENSED CASH FLOW

    (In thousands)

    (Unaudited)



















    SIX MONTHS





    ENDED





    12/31/2024



    12/31/2023

    CASH FLOWS FROM OPERATING ACTIVITIES













    Net earnings



    $

    68,490



    $

    78,459

    Adjustments to reconcile net earnings to net cash provided by operating activities













    Depreciation and amortization





    55,221





    56,343

    Costs recognized on sale of acquired inventory





    373





    364

    Deferred income taxes





    (13,417)





    (22,314)

    Stock-based compensation expense





    24,892





    22,846

    Fair value adjustment to available-for-sale investments





    —





    (283)

    (Gain) Loss on equity method investment





    (420)





    4,295

    Asset impairment restructuring





    9,841





    —

    Fair value adjustment to contingent consideration payable





    —





    (3,500)

    Impairment of assets held-for-sale





    —





    6,038

    Other operating activities





    3,255





    251

    Net cash provided by (used in) operating activities





    148,235





    142,499

    CASH FLOWS FROM INVESTING ACTIVITIES













    Proceeds from sale of available-for-sale investments





    1,085





    23,759

    Purchases of available-for-sale investments





    —





    (5,526)

    Additions to property and equipment





    (15,993)





    (28,456)

    Acquisitions, net of cash acquired





    —





    (169,707)

    Distributions from (Investments in) Wilson Wolf





    1,403





    2,149

    Investment in Spear Bio





    (15,000)





    —

    Proceeds from sale of assets held-for-sale





    1,789





    —

    Net cash provided by (used in) investing activities





    (26,716)





    (177,781)

    CASH FLOWS FROM FINANCING ACTIVITIES













    Cash dividends





    (25,424)





    (25,213)

    Proceeds from stock option exercises





    30,641





    19,670

    Long-term debt activity, net





    (19,000)





    97,000

    Re-purchases of common stock





    (75,628)





    (80,042)

    Taxes paid on RSUs and net share settlements





    (5,997)





    (21,302)

    Net cash provided by (used in) financing activities





    (95,408)





    (9,887)

    Effect of exchange rate changes on cash and cash equivalents





    (353)





    (5,270)

    Net increase (decrease) in cash and cash equivalents





    25,758





    (50,439)

    Cash and cash equivalents at beginning of period





    151,791





    180,571

    Cash and cash equivalents at end of period



    $

    177,549



    $

    130,132

     

    BT Logo (PRNewsfoto/Bio-Techne Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-second-quarter-fiscal-2025-results-302368325.html

    SOURCE Bio-Techne Corporation

    Get the next $TECH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    5/22/2024$85.00Buy → Neutral
    Citigroup
    2/8/2024$80.00Sector Outperform
    Scotiabank
    2/2/2024$65.00Buy → Hold
    Stifel
    12/7/2023$80.00Buy
    UBS
    8/28/2023Outperform
    William Blair
    More analyst ratings

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bio-Techne downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Bio-Techne from Overweight to Sector Weight

      4/9/25 8:34:38 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Bio-Techne with a new price target

      Evercore ISI initiated coverage of Bio-Techne with a rating of Outperform and set a new price target of $75.00

      3/18/25 7:57:08 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Bio-Techne from Outperform to Neutral and set a new price target of $68.00 from $88.00 previously

      2/19/25 7:06:32 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      5/5/25 4:18:21 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP - General Counsel Bohnen Shane converted options into 2,260 shares and covered exercise/tax liability with 747 shares, increasing direct ownership by 90% to 3,194 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      4/7/25 4:25:38 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herr Amy E. exercised 1,976 shares at a strike of $44.33 and sold $122,691 worth of shares (1,860 units at $65.96) (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      2/18/25 4:49:57 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

      MINNEAPOLIS, May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes

      5/8/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initia

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be r

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bio-Techne Corp

      10-Q - BIO-TECHNE Corp (0000842023) (Filer)

      5/8/25 4:30:29 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - BIO-TECHNE Corp (0000842023) (Filer)

      5/7/25 6:30:11 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne Corp filed SEC Form 8-K: Regulation FD Disclosure

      8-K - BIO-TECHNE Corp (0000842023) (Filer)

      5/6/25 4:30:10 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bio-Techne Corp

      SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

      11/14/24 1:22:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/13/24 5:00:46 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/9/23 11:12:40 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    See more

    $TECH
    Financials

    Live finance-specific insights

    See more
    • Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

      MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

      2/4/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

      MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

      4/30/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

      MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

      1/5/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initia

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be r

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne to Host Conference Call on May 7, 2025, to Announce Third Quarter Fiscal 2025 Financial Results

      MINNEAPOLIS, April 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time:            8:00 a.m. CDT Date:                      May 7, 2025 Dial-in:    1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID:      13753150 Webcast:                https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-3

      4/15/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care